{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:28:20Z","timestamp":1780496900931,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T00:00:00Z","timestamp":1264636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T00:00:00Z","timestamp":1264636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s11894-009-0080-9","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T04:52:50Z","timestamp":1264567970000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antifibrotic Therapies: Will We Ever Get There?"],"prefix":"10.1007","volume":"12","author":[{"given":"Alexander James","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,28]]},"reference":[{"key":"80_CR1","unstructured":"United Network for Organ Sharing: Online database system. Available at http:\/\/www.unos.org\/data\/. Accessed November 2009."},{"key":"80_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655\u20131669.","journal-title":"Gastroenterology"},{"key":"80_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1053\/jhep.2002.0350964","volume":"35","author":"H Jaeschke","year":"2002","unstructured":"Jaeschke H: Inflammation in response to hepatocellular apoptosis. Hepatology 2002, 35:964\u2013966.","journal-title":"Hepatology"},{"key":"80_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/nm1663","volume":"13","author":"E Seki","year":"2007","unstructured":"\u2022 Seki E, De Minicis S, Osterreicher CH, et al.: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324\u20131332. This study showed that TLR4 expression and signaling by HSCs is an important fibrogenic stimulus.","journal-title":"Nat Med"},{"key":"80_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","volume":"331","author":"WA Border","year":"1994","unstructured":"Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286\u20131292.","journal-title":"N Engl J Med"},{"key":"80_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1053\/jhep.2000.9109","volume":"32","author":"T Nakamura","year":"2000","unstructured":"Nakamura T, Sakata R, Ueno T, et al.: Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000, 32:247\u2013255.","journal-title":"Hepatology"},{"key":"80_CR7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jhep.2007.01.029","volume":"46","author":"E Borkham-Kamphorst","year":"2007","unstructured":"Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, et al.: Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007, 46:1064\u20131074.","journal-title":"J Hepatol"},{"key":"80_CR8","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/hep.20420","volume":"40","author":"S Yokohama","year":"2004","unstructured":"Yokohama S, Yoneda M, Haneda M, et al.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222\u20131225.","journal-title":"Hepatology"},{"key":"80_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jhep.2005.02.034","volume":"43","author":"L Yang","year":"2005","unstructured":"Yang L, Bataller R, Dulyx J, et al.: Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005, 43:317\u2013323.","journal-title":"J Hepatol"},{"key":"80_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1053\/gast.2002.32995","volume":"122","author":"K Ikejima","year":"2002","unstructured":"Ikejima K, Takei Y, Honda H, et al.: Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122:1399\u20131410.","journal-title":"Gastroenterology"},{"key":"80_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1517\/14728222.11.3.403","volume":"11","author":"A Mallat","year":"2007","unstructured":"Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S: Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 2007, 11:403\u2013409.","journal-title":"Expert Opin Ther Targets"},{"key":"80_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.21849","volume":"46","author":"B Wang","year":"2007","unstructured":"Wang B, Dolinski BM, Kikuchi N, et al.: Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 2007, 46:1404\u20131412.","journal-title":"Hepatology"},{"key":"80_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/17826","volume":"397","author":"L Ulloa","year":"1999","unstructured":"Ulloa L, Doody J, Massague J: Inhibition of transforming growth factor-beta\/SMAD signalling by the interferon-gamma\/STAT pathway. Nature 1999, 397:710\u2013713.","journal-title":"Nature"},{"key":"80_CR14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1053\/j.gastro.2003.08.029","volume":"125","author":"Y Kamada","year":"2003","unstructured":"Kamada Y, Tamura S, Kiso S, et al.: Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125:1796\u20131807.","journal-title":"Gastroenterology"},{"key":"80_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hep.21991","volume":"47","author":"M Adachi","year":"2008","unstructured":"Adachi M, Brenner DA: High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008, 47:677\u2013685.","journal-title":"Hepatology"},{"key":"80_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/gast.2000.9365","volume":"119","author":"F Marra","year":"2000","unstructured":"Marra F, Efsen E, Romanelli RG, et al.: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466\u2013478.","journal-title":"Gastroenterology"},{"key":"80_CR17","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/gast.2002.33666","volume":"122","author":"A Galli","year":"2002","unstructured":"Galli A, Crabb DW, Ceni E, et al.: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924\u20131940.","journal-title":"Gastroenterology"},{"key":"80_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, et al.: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005, 315:58\u201368.","journal-title":"J Pharmacol Exp Ther"},{"key":"80_CR19","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1053\/j.gastro.2009.06.051","volume":"137","author":"WK Syn","year":"2009","unstructured":"Syn WK, Jung Y, Omenetti A, et al.: Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137:1478\u20131488.","journal-title":"Gastroenterology"},{"key":"80_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303\u20131313.","journal-title":"Gastroenterology"},{"key":"80_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/hep.21492","volume":"45","author":"S Bruno","year":"2007","unstructured":"Bruno S, Stroffolini T, Colombo M, et al.: Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579\u2013587.","journal-title":"Hepatology"},{"key":"80_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, et al.: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677\u2013684.","journal-title":"Ann Intern Med"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256\u20131263.","journal-title":"N Engl J Med"},{"key":"80_CR24","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology 2006, 131:1743\u20131751.","journal-title":"Gastroenterology"},{"key":"80_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/gast.2003.50013","volume":"124","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Goldin RD, Heathcote EJ, et al.: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105\u2013117.","journal-title":"Gastroenterology"},{"key":"80_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.21260","volume":"44","author":"L Falize","year":"2006","unstructured":"Falize L, Guillygomarc\u2019h A, Perrin M, et al.: Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44:472\u2013477.","journal-title":"Hepatology"},{"key":"80_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/archinte.166.3.294","volume":"166","author":"LW Powell","year":"2006","unstructured":"Powell LW, Dixon JL, Ramm GA, et al.: Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006, 166:294\u2013301.","journal-title":"Arch Intern Med"},{"key":"80_CR28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","volume":"127","author":"JF Dufour","year":"1997","unstructured":"Dufour JF, DeLellis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997, 127:981\u2013985.","journal-title":"Ann Intern Med"},{"key":"80_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00004836-200105000-00014","volume":"32","author":"SJ Cotler","year":"2001","unstructured":"Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001, 32:428\u2013430.","journal-title":"J Clin Gastroenterol"},{"key":"80_CR30","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/hep.20251","volume":"39","author":"JB Dixon","year":"2004","unstructured":"Dixon JB, Bhathal PS, Hughes NR, O\u2019Brien PE: Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647\u20131654.","journal-title":"Hepatology"},{"key":"80_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","volume":"6","author":"RR Mummadi","year":"2008","unstructured":"Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK: Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396\u20131402.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"80_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/hep.1840130220","volume":"13","author":"F Saez-Royuela","year":"1991","unstructured":"Saez-Royuela F, Porres JC, Moreno A, et al.: High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991, 13:327\u2013331.","journal-title":"Hepatology"},{"key":"80_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1365-2893.2005.00689.x","volume":"13","author":"AJ Muir","year":"2006","unstructured":"Muir AJ, Sylvestre PB, Rockey DC: Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat 2006, 13:322\u2013328.","journal-title":"J Viral Hepat"},{"key":"80_CR34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1542-3565(05)00404-0","volume":"3","author":"HL Weng","year":"2005","unstructured":"Weng HL, Wang BE, Jia JD, et al.: Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005, 3:819\u2013828.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"80_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/hep.21561","volume":"45","author":"PJ Pockros","year":"2007","unstructured":"\u2022 Pockros PJ, Jeffers L, Afdhal N, et al.: Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007, 45:569\u2013578. Multicenter randomized controlled study failed to show a histologic benefit with the use of IFN-\u03b3.","journal-title":"Hepatology"},{"key":"80_CR36","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","volume":"359","author":"AM Di Bisceglie","year":"2008","unstructured":"\u2022 Di Bisceglie AM, Shiffman ML, Everson GT, et al.: Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429\u20132441. This study (HALT-C, along with the EPIC-3 and COPILOT studies) demonstrated that there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis.","journal-title":"N Engl J Med"},{"key":"80_CR37","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1053\/j.gastro.2009.01.039","volume":"136","author":"T Poynard","year":"2009","unstructured":"\u2022 Poynard T, Colombo M, Bruix J, et al.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa\/ribavirin therapy. Gastroenterology 2009, 136:1618\u20131628. This study (EPIC-3, along with the HALT-C and COPILOT studies) demonstrated that there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis.","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"80_CR38","first-page":"S4 (A3)","volume":"48","author":"N Afdhal","year":"2008","unstructured":"\u2022 Afdhal N, Levine R, Brown RJ, et al.: E. Colchicine vs peg-interferonalfa 2B long term therapy: results of the 4\u00a0year COPILOT trial. J Hepatol 2008, 48 (Suppl 2):S4 (A3). This study (COPILOT, and the HALT-C and EPIC-3 studies) demonstrated there is no clinical or histologic benefit from the use of maintenance low-dose pegIFN in patients with CHC and moderate-to-advanced fibrosis.","journal-title":"J Hepatol"},{"key":"80_CR39","doi-asserted-by":"publisher","first-page":"G902","DOI":"10.1152\/ajpgi.00124.2006","volume":"291","author":"L Yang","year":"2006","unstructured":"Yang L, Chan CC, Kwon OS, et al.: Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2006, 291:G902\u2013G911.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4 Suppl","key":"80_CR40","first-page":"1139A","volume":"48","author":"J McHutchison","year":"2008","unstructured":"McHutchison J, Goodman Z, Makhlouf H, et al.: Double-blind, randomized, placebo-controlled, multi-center, phase II dose-ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection. Hepatology 2008, 48(4 Suppl):1139A.","journal-title":"Hepatology"},{"key":"80_CR41","doi-asserted-by":"crossref","unstructured":"Colmenero J, Bataller R, Sancho-Bru P, et al.: Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009 (Epub ahead of print).","DOI":"10.1152\/ajpgi.00162.2009"},{"key":"80_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/hep.21664","volume":"46","author":"PJ Pockros","year":"2007","unstructured":"Pockros PJ, Schiff ER, Shiffman ML, et al.: Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007, 46:324\u2013329.","journal-title":"Hepatology"},{"key":"80_CR43","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.23167","volume":"50","author":"RP Witek","year":"2009","unstructured":"Witek RP, Stone WC, Karaca FG, et al.: Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50:1421\u20131430.","journal-title":"Hepatology"},{"key":"80_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","volume":"135","author":"E Patsenker","year":"2008","unstructured":"\u2022 Patsenker E, Popov Y, Stickel F, et al.: Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660\u2013670. This study demonstrated that inhibitors \u03b1v\u03b26 integrin have antifibrotic potential.","journal-title":"Gastroenterology"},{"key":"80_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.107.131896","volume":"324","author":"J Munoz-Luque","year":"2008","unstructured":"Munoz-Luque J, Ros J, Fernandez-Varo G, et al.: Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008, 324:475\u2013483.","journal-title":"J Pharmacol Exp Ther"},{"key":"80_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nm1421","volume":"12","author":"F Teixeira-Clerc","year":"2006","unstructured":"Teixeira-Clerc F, Julien B, Grenard P, et al.: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671\u2013676.","journal-title":"Nat Med"},{"key":"80_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jhep.2008.01.032","volume":"49","author":"A Douglass","year":"2008","unstructured":"Douglass A, Wallace K, Parr R, et al.: Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008, 49:88\u201398.","journal-title":"J Hepatol"},{"key":"80_CR48","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/hep.23162","volume":"50","author":"ND Freedman","year":"2009","unstructured":"Freedman ND, Everhart JE, Lindsay KL, et al.: Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50:1360\u20131369.","journal-title":"Hepatology"},{"key":"80_CR49","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/hep.23123","volume":"50","author":"Y Popov","year":"2009","unstructured":"Popov Y, Schuppan D: Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies. Hepatology 2009, 50:1294\u20131306.","journal-title":"Hepatology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-009-0080-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0080-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-009-0080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T20:56:09Z","timestamp":1744059369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-009-0080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1007\/s11894-009-0080-9","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,28]]},"assertion":[{"value":"28 January 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}